tert-butyl N-[(2R,3aR,6aR)-6a-(3-propan-2-yloxy-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl)-2,3,3a,4,5,6-hexahydro-1H-pentalen-2-yl]carbamate | 1422437-01-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[(2R,3aR,6aR)-6a-(3-propan-2-yloxy-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl)-2,3,3a,4,5,6-hexahydro-1H-pentalen-2-yl]carbamate
• CAS: 1422437-01-1
• 化学式: C₂₅H₃₇N₃O₄
• 分子量: 443.586
• InChiKey: XRZIJGUALHGOCL-MPCDZSKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(2R,3aR,6aR)-6a-(3-propan-2-yloxy-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl)-2,3,3a,4,5,6-hexahydro-1H-pentalen-2-yl]carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists

  摘要：

  Novel CCR2 antagonists with a novel 2-aminooctahydrocyclopentalene-3a-carboxamide scaffold were designed. SAR studies led to a series of potent compounds. For example, compound 51 had a good PK profile in both dog and monkey, and exhibited excellent efficacy when dosed orally in an inflammation model in hCCR2 KI mice. In addition, an asymmetric synthesis to the core structures was developed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.069
• 作为产物：
  描述：

  (2R,3aR,6aR)-methyl 2-(bis(tert-butoxycarbonyl)amino)-5-methyleneoctahydropentalene-3a-carboxylate 在 水 、 1-羟基苯并三唑 、 臭氧 、 sodium sulfate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 对甲苯磺酰肼 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 生成 tert-butyl N-[(2R,3aR,6aR)-6a-(3-propan-2-yloxy-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl)-2,3,3a,4,5,6-hexahydro-1H-pentalen-2-yl]carbamate
  参考文献：
  名称：

  Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists

  摘要：

  Novel CCR2 antagonists with a novel 2-aminooctahydrocyclopentalene-3a-carboxamide scaffold were designed. SAR studies led to a series of potent compounds. For example, compound 51 had a good PK profile in both dog and monkey, and exhibited excellent efficacy when dosed orally in an inflammation model in hCCR2 KI mice. In addition, an asymmetric synthesis to the core structures was developed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.069